Pulmonary fibrosis is a progressive, irreversible scarring of lung tissue that steadily robs patients of their ability to breathe. Idiopathic pulmonary fibrosis (IPF) — the most common form — carries a median survival of just 3–5 years from diagnosis, worse than many cancers. Current antifibrotic drugs (pirfenidone, nintedanib) slow decline but do not stop or reverse the scarring process. Mesenchymal stem cell (MSC) therapy is being investigated as a way to interrupt the fibrotic cascade at the cellular level — not by replacing scarred tissue, but by altering the signaling environment that drives fibrosis forward.[1][2]

Scientific medical illustration of MSCs releasing anti-fibrotic factors within fibrotic lung tissue — deep navy and clinical blue editorial biotech aesthetic
The therapeutic rationale for MSCs in pulmonary fibrosis centers on paracrine signaling — transplanted cells release anti-fibrotic factors (HGF, KGF, PGE2) and immunomodulatory cytokines that may interrupt the scar-forming cycle, rather than physically replacing damaged lung architecture.

What Is Pulmonary Fibrosis?

Pulmonary fibrosis is progressive scarring (fibrosis) of the lung interstitium — the delicate connective tissue scaffold that supports the alveoli, where oxygen and carbon dioxide exchange. As scar tissue accumulates, the alveolar walls thicken and stiffen, reducing the lungs' ability to expand and transfer oxygen into the bloodstream.[3]

Where the damage begins. The prevailing model holds that repeated micro-injury to the alveolar epithelium — from environmental exposures, gastroesophageal reflux, viral infections, or genetic predisposition — triggers an aberrant wound-healing response. Instead of resolving, fibroblasts are persistently activated into myofibroblasts that deposit excessive extracellular matrix proteins, particularly collagen. The result is a self-perpetuating cycle: stiff tissue → mechanical stress on adjacent alveoli → further injury → more fibrosis.[4][5]

Why conventional treatments stall. Pirfenidone and nintedanib target specific profibrotic pathways (TGF-β, PDGF, FGF), and clinical trials show they reduce the rate of forced vital capacity (FVC) decline by approximately 50%. But they do not halt progression entirely, carry significant side effects (gastrointestinal distress, photosensitivity, liver toxicity), and do not restore lost lung function. The fundamental barrier remains: once the fibrotic program is locked in, dampening one pathway is not enough to switch it off.[6]

How MSC Therapy Targets Pulmonary Fibrosis

MSCs address fibrosis through multiple mechanisms simultaneously. Unlike single-pathway antifibrotic drugs, MSCs secrete a broad repertoire of bioactive molecules — the "secretome" — that collectively suppress inflammation, induce myofibroblast apoptosis, degrade excess extracellular matrix, and stimulate endogenous repair.[7][8]

Key MSC mechanisms in pulmonary fibrosis:
  • Anti-fibrotic factors: Hepatocyte growth factor (HGF) and keratinocyte growth factor (KGF) directly counter TGF-β-driven myofibroblast activation and collagen synthesis.
  • Immunomodulation: MSCs shift macrophages from a profibrotic M2 phenotype toward an antifibrotic M1/M2 balance, reducing IL-4/IL-13-driven collagen deposition. PGE2 secretion suppresses T-cell proliferation.
  • Matrix remodeling: MSCs upregulate matrix metalloproteinases (MMPs) that degrade excess collagen while downregulating TIMPs (tissue inhibitors of metalloproteinases), tipping the balance toward scar resolution.
  • Mitochondrial transfer: MSCs can transfer healthy mitochondria to injured alveolar epithelial cells via tunneling nanotubes, restoring cellular bioenergetics and reducing apoptosis.

HGF is particularly relevant. In bleomycin-induced mouse models of pulmonary fibrosis, MSC-derived HGF reduced collagen deposition by 40–60% and improved survival. The effect was abolished when HGF was blocked, confirming the centrality of this single factor. Human MSCs produce HGF constitutively, and the levels increase further when the cells are exposed to inflammatory signals — precisely the environment they encounter in a fibrotic lung.[9][10]

Clinical Evidence: What the Trials Show

Clinical data remain early-stage but directionally encouraging. The majority of published studies in pulmonary fibrosis are Phase I safety trials or small Phase I/II pilots. No Phase III registrational trial has been completed — and this honest acknowledgement is essential for patients evaluating their options.

Phase I Safety (2017)

Chambers et al. administered placental MSCs (1–2 × 10⁶ cells/kg IV) to 8 IPF patients. No serious adverse events at 6-month follow-up. FVC and 6MWT remained stable — notable in a population where decline is expected. [11]

Phase I Safety (2019)

Glassberg et al. tested bone marrow MSCs (20–200 × 10⁶ cells IV) in 9 IPF patients. Treatment was well-tolerated. FVC, DLCO, and 6MWT showed trends toward stabilization at 12 months. [12]

Phase Ib (2020)

Averyanov et al. delivered high-dose bone marrow MSCs (2 × 10⁶ cells/kg IV monthly × 4) to 13 IPF patients. At 12 months, FVC was preserved while matched controls declined. CT fibrosis score was stable in the MSC group. [13]

Interpreting the data honestly. Across these studies, the consistent finding is safety — no ectopic tissue formation, no significant immune reactions, and no tumorigenic events. Efficacy signals (FVC stability, 6MWT maintenance, reduced inflammatory biomarkers) are encouraging but come from trials too small to draw definitive conclusions. Every published paper emphasizes that larger, randomized, placebo-controlled trials are needed before MSC therapy can be considered a standard-of-care option for pulmonary fibrosis.

What Is the Treatment Protocol?

MSC therapy for pulmonary fibrosis is typically delivered intravenously. The IV route allows cells to pass through the pulmonary circulation first — a phenomenon called "first-pass lung trapping" — where MSCs transiently lodge in the lung microvasculature before redistributing. Far from being a limitation, this pulmonary trapping may be therapeutic: MSCs retained in the lung continue secreting paracrine factors at the site of disease.[14]

Sourcing

Umbilical cord-derived MSCs (Wharton's Jelly) — selected for high proliferative capacity, low immunogenicity, and robust HGF/KGF expression profile.

Dosing

Typically 100–200 million MSCs per IV infusion. Protocols often include 2–4 sessions spaced 4–8 weeks apart, tailored to disease severity and patient response.

Monitoring

Pulmonary function tests (FVC, DLCO), 6-minute walk test, HRCT fibrosis scoring, and quality-of-life questionnaires (SGRQ, UCSD-SOBQ) at baseline and 3–6 month intervals.

Safety and Limitations

MSC therapy for pulmonary fibrosis has a well-documented short-term safety profile. Across all published IPF trials, adverse events have been mild and transient — low-grade fever, transient fatigue, and occasional infusion-related discomfort. No cases of ectopic tissue formation, pulmonary embolism from cell clumping, or tumorigenesis have been reported in the pulmonary fibrosis literature specifically.[15]

Honest limitations every patient should understand:
  • No Phase III trial has demonstrated efficacy — the therapy remains investigational for pulmonary fibrosis.
  • The optimal cell source (bone marrow vs. umbilical cord vs. adipose), dose, and dosing frequency are not yet established.
  • MSCs are not a cure. The goal is disease modification — slowing or stabilizing fibrosis — not reversal of established scar tissue.
  • Patients with advanced disease (FVC < 50% predicted, on supplemental oxygen) have been excluded from most trials; safety and efficacy in this population are even less certain.
  • Intravenous delivery results in significant first-pass lung trapping; while this may be therapeutic, the fraction of cells that engraft long-term is negligible.

Why Patients Consider Treatment in Bangkok

Thailand — and Bangkok specifically — has emerged as a destination for patients seeking MSC therapy for pulmonary fibrosis. Several factors contribute: a regulatory framework that permits clinical MSC use under physician supervision, GMP-compliant cell manufacturing facilities, and treatment costs significantly lower than equivalent care in North America or Europe.[16]

The VELAR approach. Patients considering MSC therapy at VELAR Center undergo comprehensive pulmonary evaluation — HRCT imaging, full PFTs including DLCO, 6MWT, and inflammatory biomarker panels — before any treatment decision. Dosing is individualized based on disease severity, and every patient receives honest counsel about what the current evidence does and does not support.

Frequently Asked Questions

Can stem cells cure pulmonary fibrosis?

No. MSCs are not a cure for pulmonary fibrosis. The goal of MSC therapy is disease modification — slowing or stabilizing the progression of fibrosis — not reversal of established scar tissue. Early trials show signals of FVC stabilization, but no study has demonstrated fibrosis reversal.

How much does stem cell therapy for pulmonary fibrosis cost in Thailand?

Treatment costs vary based on cell dose, number of sessions, and individual clinical needs. As a reference, MSC therapy in Thailand typically ranges from $8,000–$18,000 USD per treatment course, substantially less than comparable programs in the United States or Europe.

Is intravenous MSC delivery effective for lung conditions?

IV-delivered MSCs are trapped in the pulmonary microvasculature on first pass — a phenomenon that concentrates the cells in the lungs. While long-term engraftment is minimal, the retained cells secrete antifibrotic and immunomodulatory factors (HGF, KGF, PGE2) that may exert therapeutic effects for 48–72 hours post-infusion.

What is the difference between MSC therapy and antifibrotic drugs?

Antifibrotic drugs (pirfenidone, nintedanib) target single molecular pathways to slow fibrosis. MSCs address multiple pathways simultaneously — suppressing TGF-β, modulating macrophages, degrading excess collagen, and supporting epithelial repair — through their paracrine secretome. Some researchers believe this multi-target approach may offer advantages, but this hypothesis has not been proven in head-to-head trials.

Are there any risks specific to pulmonary fibrosis patients?

Patients with advanced disease (FVC below 50% predicted, significant oxygen dependence) have been excluded from most trials, so the safety profile in this population is less established. Pre-existing pulmonary hypertension — common in advanced IPF — could theoretically increase the risk of microvascular complications from IV cell infusion, though this has not been observed in published studies.

Bottom line: MSC therapy for pulmonary fibrosis is an investigational approach with a favorable early safety record and mechanistic rationale supported by preclinical and early clinical data. It is not a cure, it is not proven in Phase III trials, and it should only be pursued after thorough consultation with both a pulmonologist and a regenerative medicine specialist who can provide an honest assessment of its current evidentiary standing.

References

  1. Richeldi L, Collard HR, Jones MG. Idiopathic pulmonary fibrosis. The Lancet. 2017;389(10082):1941-1952. doi:10.1016/S0140-6736(17)30866-8 ↩
  2. Lederer DJ, Martinez FJ. Idiopathic pulmonary fibrosis. New England Journal of Medicine. 2018;378(19):1811-1823. doi:10.1056/NEJMra1705751 ↩
  3. Wynn TA. Integrating mechanisms of pulmonary fibrosis. Journal of Experimental Medicine. 2011;208(7):1339-1350. doi:10.1084/jem.20110551 ↩
  4. Wolters PJ, Collard HR, Jones KD. Pathogenesis of idiopathic pulmonary fibrosis. Annual Review of Pathology. 2014;9:157-179. doi:10.1146/annurev-pathol-012513-104706 ↩
  5. Chanda D, Otoupalova E, Smith SR, Volckaert T, De Langhe SP, Thannickal VJ. Developmental pathways in the pathogenesis of lung fibrosis. Molecular Aspects of Medicine. 2019;65:56-69. doi:10.1016/j.mam.2018.08.004 ↩
  6. Flaherty KR, Wells AU, Cottin V, et al. Nintedanib in progressive fibrosing interstitial lung diseases. New England Journal of Medicine. 2019;381(18):1718-1727. doi:10.1056/NEJMoa1908681 ↩
  7. Tzouvelekis A, Toonkel R, Karampitsakos T, et al. Mesenchymal stem cells for the treatment of idiopathic pulmonary fibrosis. Frontiers in Medicine. 2018;5:142. doi:10.3389/fmed.2018.00142 ↩
  8. Ntolios P, Janning M, Stathopoulos GT, et al. The role of mesenchymal stem cells in idiopathic pulmonary fibrosis. European Respiratory Review. 2022;31(166):220084. doi:10.1183/16000617.0084-2022 ↩
  9. Gazdhar A, Grad I, Tamò L, et al. The secretome of induced pluripotent stem cells reduces lung fibrosis in part by hepatocyte growth factor. Stem Cell Research & Therapy. 2014;5(6):123. doi:10.1186/scrt513 ↩
  10. Cahill EF, Kennelly H, Carty F, Mahon BP, English K. Hepatocyte growth factor is required for mesenchymal stromal cell protection against bleomycin-induced pulmonary fibrosis. Stem Cells Translational Medicine. 2016;5(8):1117-1127. doi:10.5966/sctm.2015-0337 ↩
  11. Chambers DC, Enever D, Ilic N, et al. A phase 1b study of placenta-derived mesenchymal stromal cells in patients with idiopathic pulmonary fibrosis. Respirology. 2014;19(7):1013-1018. doi:10.1111/resp.12343 ↩
  12. Glassberg MK, Minkiewicz J, Toonkel RL, et al. Allogeneic human mesenchymal stem cells in patients with idiopathic pulmonary fibrosis via intravenous delivery (AETHER): a phase I safety clinical trial. Chest. 2017;151(5):971-981. doi:10.1016/j.chest.2016.11.050 ↩
  13. Averyanov A, Koroleva I, Konoplyannikov M, et al. First-in-human high-cumulative-dose stem cell therapy in idiopathic pulmonary fibrosis with rapid lung function decline. Stem Cells Translational Medicine. 2020;9(1):6-16. doi:10.1002/sctm.19-0037 ↩
  14. Fischer UM, Harting MT, Jimenez F, et al. Pulmonary passage is a major obstacle for intravenous stem cell delivery: the pulmonary first-pass effect. Stem Cells and Development. 2009;18(5):683-692. doi:10.1089/scd.2008.0253 ↩
  15. Lalu MM, McIntyre L, Pugliese C, et al. Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis of clinical trials. PLoS ONE. 2012;7(10):e47559. doi:10.1371/journal.pone.0047559 ↩
  16. Sueblinvong V, Weiss DJ. Stem cells and cell therapy approaches in lung biology and diseases. Translational Research. 2010;156(3):189-204. doi:10.1016/j.trsl.2010.06.006 ↩